Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.98 0.00 (0.00%)
As of 11:58 AM Eastern
Compare

BPCR vs. BRIG, LGT, RIV, SGEM, and NBMI

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include BlackRock Income and Growth (BRIG), Lighthouse Group (LGT), River and Mercantile Group (RIV), ScotGems (SGEM), and NB Global Monthly Income Fund Ltd GBP (NBMI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does BioPharma Credit compare to BlackRock Income and Growth?

BioPharma Credit (LON:BPCR) and BlackRock Income and Growth (LON:BRIG) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

BioPharma Credit has higher revenue and earnings than BlackRock Income and Growth. BioPharma Credit is trading at a lower price-to-earnings ratio than BlackRock Income and Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.09
BlackRock Income and Growth£7.07M6.19£6.90M£34.866.77

BioPharma Credit has a beta of 0.22688746, suggesting that its share price is 77% less volatile than the broader market. Comparatively, BlackRock Income and Growth has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

31.3% of BioPharma Credit shares are owned by institutional investors. Comparatively, 0.7% of BlackRock Income and Growth shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Comparatively, 3.8% of BlackRock Income and Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to BlackRock Income and Growth's net margin of 88.25%. BlackRock Income and Growth's return on equity of 14.31% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
BlackRock Income and Growth 88.25%14.31%2.59%

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. BlackRock Income and Growth pays an annual dividend of GBX 7.70 per share and has a dividend yield of 3.3%. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BlackRock Income and Growth pays out 22.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BioPharma Credit's average media sentiment score of 0.76 beat BlackRock Income and Growth's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Positive
BlackRock Income and Growth Neutral

Summary

BioPharma Credit and BlackRock Income and Growth tied by winning 7 of the 14 factors compared between the two stocks.

How does BioPharma Credit compare to Lighthouse Group?

Lighthouse Group (LON:LGT) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lighthouse Group£53.42M0.00N/A£1.80N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

In the previous week, BioPharma Credit's average media sentiment score of 0.76 beat Lighthouse Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.

Company Overall Sentiment
Lighthouse Group Neutral
BioPharma Credit Positive

BioPharma Credit has a net margin of 92.62% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Lighthouse GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioPharma Credit beats Lighthouse Group on 9 of the 11 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

River and Mercantile Group (LON:RIV) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
River and Mercantile Group£74.82M0.00N/A-£2.20N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

In the previous week, BioPharma Credit's average media sentiment score of 0.76 beat River and Mercantile Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.

Company Overall Sentiment
River and Mercantile Group Neutral
BioPharma Credit Positive

BioPharma Credit has a net margin of 92.62% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
River and Mercantile GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

BioPharma Credit beats River and Mercantile Group on 10 of the 11 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

ScotGems (LON:SGEM) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, BioPharma Credit's average media sentiment score of 0.76 beat ScotGems' score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.

Company Overall Sentiment
ScotGems Neutral
BioPharma Credit Positive

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
ScotGemsN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScotGems£5.07M0.00N/A£0.07N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

Summary

BioPharma Credit beats ScotGems on 10 of the 11 factors compared between the two stocks.

How does BioPharma Credit compare to NB Global Monthly Income Fund Ltd GBP?

BioPharma Credit (LON:BPCR) and NB Global Monthly Income Fund Ltd GBP (LON:NBMI) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

BioPharma Credit has a net margin of 92.62% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat NB Global Monthly Income Fund Ltd GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
NB Global Monthly Income Fund Ltd GBP N/A N/A N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.09
NB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17N/A

31.3% of BioPharma Credit shares are held by institutional investors. Comparatively, 44.3% of NB Global Monthly Income Fund Ltd GBP shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by insiders. Comparatively, 0.2% of NB Global Monthly Income Fund Ltd GBP shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, BioPharma Credit's average media sentiment score of 0.76 beat NB Global Monthly Income Fund Ltd GBP's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Positive
NB Global Monthly Income Fund Ltd GBP Neutral

Summary

BioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 8 of the 11 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£11.00M£5.71B£14.06B£2.93B
Dividend Yield7.16%7.40%5.89%6.17%
P/E Ratio0.0932.5526.70367.32
Price / Sales0.081,229.32516.4883,741.35
Price / Cash1.1948.3338.5027.89
Price / Book0.012.132.187.02
Net Income£10.42B£417.46M£1.31B£5.89B
7 Day Performance0.41%0.60%1.38%0.89%
1 Month Performance1.24%2.36%2.93%3.27%
1 Year Performance8.65%7.75%11.49%22.28%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.98
flat		N/A+7.8%£11.00M£132.06M0.09N/A
BRIG
BlackRock Income and Growth
N/AGBX 232.44
-0.7%		N/A+11.8%£43.08M£7.07M6.67N/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300
SGEM
ScotGems
N/AN/AN/AN/A£42.02M£5.07M1,121.43N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
The Rumors About Elon’s Next Move Are Spreading Fast
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump’s new dollar decree
The last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel